Stocktoria
Medinotec Inc. MDNC
Medinotec Inc. (MDNC) earns a Piotroski F-score of 5/9 (mixed financial health). It does not currently pay a dividend. FY2026 revenue was $9.7M at a 8.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.25 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| NXGL | NEXGEL, INC. | 5/9 | -6.91 | — | — |
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
About Medinotec Inc.
Medinotec Inc. engages in the research and development, production, and sale of medical devices used in cardiology and airway-related procedures in South Africa, the United States, and internationally. The company offers semi-compliant percutaneous transluminal coronary angioplasty balloon catheters, suction dissectors, aortic perfusion and dilation catheters, chronic total occlusion catheters, and silicone tracheal stents; and distributes a range of cardiology and renal dialysis products. It serves hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. The company sells its products through the network of distributors and direct sales force. Medinotec Inc. was incorporated in 2021 and is headquartered in Johannesburg, South Africa.
FAQ
Is MDNC financially healthy?
Medinotec Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does MDNC pay a dividend?
No, Medinotec Inc. does not currently pay a dividend.
How profitable is MDNC?
In FY2026, Medinotec Inc. had a net margin of 8.2% and a return on equity of 13.9%.
What is MDNC's P/E ratio?
Medinotec Inc.'s trailing price-to-earnings (P/E) ratio is about 74.0×, based on its latest annual earnings.
Is MDNC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Medinotec Inc.: a Piotroski F-score of 5/9, a P/E of about 74.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-02-28. Facts plus Stocktoria's own computed scores — not investment advice.